Inj ustekinumab-aekn, 1 mg
Products billed under this code include Selarsdi, Ustekinumab-AEKN.
Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Selarsdi, Ustekinumab-AEKN.
Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Selarsdi | Nupathe Inc | 51759-0505-13 | 45 | $471.60 |
| Selarsdi | Nupathe Inc | 51759-0505-32 | 45 | $471.60 |
| Selarsdi | Nupathe Inc | 51759-0607-32 | 90 | $943.20 |
| Selarsdi | Nupathe Inc | 51759-0708-13 | 130 | $1,362.40 |
| Ustekinumab-AEKN | Nupathe Inc | 51759-0413-32 | 45 | $471.60 |
| Ustekinumab-AEKN | Nupathe Inc | 51759-0414-32 | 90 | $943.20 |
| Ustekinumab-AEKN | Nupathe Inc | 51759-0709-32 | 45 | $471.60 |
| Ustekinumab-AEKN | Nupathe Inc | 51759-0710-32 | 90 | $943.20 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $10.48 | −$0.049 | 1 MG | Inj ustekinumab-aekn, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $10.529 | −$0.609 | 1 MG | Inj ustekinumab-aekn, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $11.138 | −$32.063 | 1 MG | Inj ustekinumab-aekn, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $43.201 | +$5.681 | 1 MG | Inj ustekinumab-aekn, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $37.52 | – | 1 MG | Inj ustekinumab-aekn, 1 mg | v1, posted September 8, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.